{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:04:27Z","timestamp":1792800267760,"version":"4.5.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Irritable bowel syndrome (IBS) is a severe gastrointestinal condition with symptoms like pain, bloating, diarrhea, and constipation. Glucagon-like peptide-1 (GLP-1) receptors, expressed in the central nervous system and peripheral tissues, have been found to affect gut motility. GLP-1 and its analog ROSE-010 have been shown to inhibit the migrating motor complex and decrease gastrointestinal motility in IBS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This systematic review and meta-analysis aim to assess the efficacy and safety of GLP-1 receptor agonists in providing pain and symptom relief for individuals with IBS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study conducted extensive searches across various databases, including Cochrane Library, Web of Science, PubMed, Google Scholar, and Science Direct, to identify studies on IBS and related drugs. A search strategy using keywords and medical subject heading terms (MeSH) was developed to ensure inclusivity. Exclusion criteria included non-English language studies, books, conference papers, case reports, <jats:italic>in vitro<\/jats:italic> studies, animal studies, and non-original articles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study found that ROSE-010 (100 \u00b5g) significantly lowered pain intensity in IBS patients compared to a placebo, with an overall odds ratio of 2.30, 95% CI: 1.53-3.46. ROSE-010 (300 \u00b5g) is more effective than a placebo for all irritable bowel syndrome subtypes, with consistent effects across trials. ROSE-010 is linked to a greater incidence of nausea, vomiting, and headache than placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ROSE-010, a glucagon-like peptide-1 receptor agonist, has been shown to reduce pain in individuals with IBS. However, its higher frequency of nausea, vomiting, and headache suggests the need for close monitoring and individualized treatment plans. Further investigation is needed to understand its impact on different IBS subtypes and long-term effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>, identifier CRD42024613545.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1548346","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T05:12:12Z","timestamp":1741669932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Mohamed E. A.","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Alrasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.jemep.2022.100857","article-title":"Living with irritable bowel syndrome: a significant impact on patients\u2019 everyday lives","volume":"26","author":"Nevots","year":"2023","journal-title":"Ethics Med Public Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.3390\/jcm13226948","article-title":"A review of pharmacologic and non-pharmacologic therapies in the management of irritable bowel syndrome: current recommendations and evidence","volume":"13","author":"Papale","year":"2024","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22532","article-title":"Diagnosis and treatment of irritable bowel syndrome: a review","volume":"325","author":"Camilleri","year":"2021","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5056\/jnm20109","article-title":"Parental, perinatal, and childhood risk factors for development of irritable bowel syndrome: a systematic review","volume":"26","author":"Low","year":"2020","journal-title":"J Neurogastroenterol motility"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00713-4","article-title":"Immune activation in irritable bowel syndrome: what is the evidence","volume":"22","author":"Aguilera-Lizarraga","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cdd.2016.17.issue-9","article-title":"Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators","volume":"17","author":"Martin-Vi\u00f1as","year":"2016","journal-title":"J digestive diseases"},{"key":"B7","first-page":"224","article-title":"Psychological disorders in gastrointestinal disease: epiphenomenon, cause or consequence","volume":"27","author":"Shah","year":"2014","journal-title":"Ann Gastroenterology: Q Publ Hellenic Soc Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.06.009","article-title":"The effect of anxiety and depression on the risk of irritable bowel syndrome in migraine patients","volume":"44","author":"Wu","year":"2017","journal-title":"J Clin Neurosci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_128","article-title":"Irritable bowel syndrome and stress-related psychiatric co-morbidities: focus on early life stress","volume":"239","author":"O\u2019Mahony","year":"2017","journal-title":"Gastrointestinal Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/SGA.0000000000000530","article-title":"Health-related quality of life in irritable bowel syndrome: a systematic review and meta-analysis","volume":"43","author":"Cassar","year":"2020","journal-title":"Gastroenterol nursing"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2022.2041084","article-title":"Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics","volume":"57","author":"Touny","year":"2022","journal-title":"Scandinavian J Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02006","article-title":"Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans","volume":"103","author":"Halim","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00175.2021","article-title":"Mechanisms underlying the prokinetic effects of endogenous glucagon-like peptide-1 in the rat proximal colon","volume":"321","author":"Nakamori","year":"2021","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S312527","article-title":"An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2is)","volume":"14","author":"Wen","year":"2021","journal-title":"Diabetes Metab Syndrome Obes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00429-020-02189-1","article-title":"Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain","volume":"226","author":"Farkas","year":"2021","journal-title":"Brain Structure Funct"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/nu12113304","article-title":"Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress","volume":"12","author":"Diz-Chaves","year":"2020","journal-title":"Nutrients"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bph.v179.4","article-title":"Actions of glucagon-like peptide-1 receptor ligands in the gut","volume":"179","author":"Holst","year":"2022","journal-title":"Br J Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.31.1_supplement.888.5","article-title":"Identification of expression and function of the glucagon-like peptide-1 receptor in gastrointestinal smooth muscle","volume":"31","author":"May","year":"2017","journal-title":"FASEB"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2012.08.009","article-title":"Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat","volume":"179","author":"Hellstr\u00f6m","year":"2012","journal-title":"Regul Peptides"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00076.2012","article-title":"Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome","volume":"303","author":"Camilleri","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.01079.x","article-title":"GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome","volume":"20","author":"Hellstr\u00f6m","year":"2008","journal-title":"Neurogastroenterol Motility"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2013.1252","article-title":"Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models","volume":"31","author":"Chen","year":"2013","journal-title":"Int J Mol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1365-2036.2008.03870.x","article-title":"Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study","volume":"29","author":"Hellstr\u00f6m","year":"2009","journal-title":"Alimentary Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13738","article-title":"The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome","volume":"32","author":"O\u2019Brien","year":"2020","journal-title":"Neurogastroenterol Motility"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198024","article-title":"Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons","volume":"13","author":"Anand","year":"2018","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2016.18.issue-3","article-title":"Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2016.12.007","article-title":"Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome","volume":"41","author":"Li","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/17425255.2020.1767067","article-title":"An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome","volume":"16","author":"Mousavi","year":"2020","journal-title":"Expert Opin Drug Metab toxicology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2017.19.issue-3","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs context"},{"key":"B32","doi-asserted-by":"publisher","first-page":"14309","DOI":"10.14309\/crj.0000000000000868","article-title":"Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice","volume":"10","author":"Camilleri","year":"2022","journal-title":"Off J Am Coll Gastroenterology| ACG"},{"key":"B33","unstructured":"PRISMA 2020 checklist"},{"key":"B34","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B35","unstructured":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-018-0034-5","article-title":"New treatments and therapeutic targets for IBS and other functional bowel disorders","volume":"15","author":"Simr\u00e9n","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.3390\/jcm11154269","article-title":"Abdominal pain in inflammatory bowel diseases: a clinical challenge","volume":"11","author":"Wils","year":"2022","journal-title":"J Clin Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001306","article-title":"Abdominal pain and depression, not bowel habits, predict health care utilization in patients with functional bowel disorders","volume":"116","author":"Yu","year":"2021","journal-title":"Off J Am Coll Gastroenterology| ACG"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16550","article-title":"current and future treatment approaches for pain in IBS","volume":"54","author":"Paine","year":"2021","journal-title":"Alimentary Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae084","article-title":"Challenges in IBD research 2024: precision medicine","volume":"30","author":"Syed","year":"2024","journal-title":"Inflammatory Bowel Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"108270","DOI":"10.1016\/j.pharmthera.2022.108270","article-title":"Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities","volume":"239","author":"Shao","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01342-8","article-title":"GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation","volume":"56","author":"Go","year":"2024","journal-title":"Exp Mol Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review","volume":"25","author":"Halloum","year":"2024","journal-title":"J Headache Pain"},{"key":"B44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/14656566.2019.1688784","article-title":"Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome","volume":"21","author":"Niewinna","year":"2020","journal-title":"Expert Opin Pharmacotherapy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2011.36.9.1665562","article-title":"Irritable bowel syndrome-Principles and novel treatment options","volume":"36","author":"Hellstrom","year":"2011","journal-title":"Drugs Future"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2366993","article-title":"Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome","volume":"25","author":"Biniszewska","year":"2024","journal-title":"Expert Opin Pharmacotherapy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front endocrinology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-019-01698-z","article-title":"Role of glucagon-like peptides in inflammatory bowel diseases\u2014current knowledge and future perspectives","volume":"392","author":"Zatorski","year":"2019","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1113\/eph.2019.104.issue-1","article-title":"Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome","volume":"104","author":"O'Malley","year":"2019","journal-title":"Exp Physiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X09104794","article-title":"The treatment of irritable bowel syndrome","volume":"2","author":"Lacy","year":"2009","journal-title":"Therap Adv Gastroenterol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381517-0.00012-6","article-title":"Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility","volume":"84","author":"Hellstr\u00f6m","year":"2010","journal-title":"Vitam Horm"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.2010.02150.x","article-title":"GLP-1 playing the role of a gut regulatory compound","volume":"201","author":"Hellstr\u00f6m","year":"2011","journal-title":"Acta PHYSIOLOGICA"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes","volume":"68","author":"Graaf","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1159\/000500602","article-title":"Targeting the enteric nervous system to treat metabolic disorders? \"Enterosynes\" as therapeutic gut factors","volume":"110","author":"Knauf","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","article-title":"The structure and function of the glucagon-like peptide-1 receptor and its ligands","volume":"166","author":"Donnelly","year":"2012","journal-title":"Br J Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"B58","article-title":"Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity","volume":"65","author":"Yang","year":"2014","journal-title":"J Physiol Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02068.x","article-title":"Modulation of gastrointestinal function by MuDelta, a mixed \u00b5 opioid receptor agonist\/ \u00b5 opioid receptor antagonist","volume":"167","author":"Wade","year":"2012","journal-title":"Br J Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.04.016","article-title":"AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation","volume":"163","author":"Chang","year":"2022","journal-title":"Gastroenterology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8860","article-title":"Small intestinal bacterial overgrowth: comprehensive review of diagnosis, prevention, and treatment methods","volume":"12","author":"Achufusi","year":"2020","journal-title":"Cureus"},{"key":"B63","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1111\/apt.v54.s1","article-title":"Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M)","author":"Nee","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1186639","article-title":"Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation","volume":"15","author":"Ponziani","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03721.x","article-title":"Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study","volume":"28","author":"Jarcho","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1756284818771674","DOI":"10.1177\/1756284818771674","article-title":"Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint","volume":"11","author":"Lacy","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13491798","article-title":"A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program","volume":"6","author":"Tong","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"B68","first-page":"17","article-title":"Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics)","volume":"18","author":"Khalif","year":"2009","journal-title":"J Gastrointestin Liver Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1548346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T05:12:22Z","timestamp":1741669942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1548346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":68,"alternative-id":["10.3389\/fendo.2025.1548346"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1548346","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"article-number":"1548346"}}